

Yongsik Jung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3358582/publications.pdf>

Version: 2024-02-01

51
papers

626
citations

686830

13
h-index

642321

23
g-index

52
all docs

52
docs citations

52
times ranked

1173
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract OT1-04-02: The NAUTILUS trial (No Axillary sUrgical Treatment In clinically Lymph node) Tj ETQq1 1 0.784314 rgBT /Overlock 11 (NCT04303715). Cancer Research, 2022, 82, OT1-04-02-OT1-04-02.	0.4	0
2	A World Weâ€™ve Never Experienced Before: Installation of Closed-Circuit Televisions in Operating Rooms. Journal of Korean Medical Science, 2022, 37, e132.	1.1	1
3	Breast density reduction as a predictor for prognosis in premenopausal women with hormone receptorâ€™positive breast cancer: A retrospective analysis of the ASTRRA study.. Journal of Clinical Oncology, 2022, 40, 531-531.	0.8	0
4	Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.. Journal of Clinical Oncology, 2022, 40, 506-506.	0.8	10
5	Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). Journal of Breast Cancer, 2021, 24, 164.	0.8	2
6	Local Recurrence in Young Women with Breast Cancer: Breast Conserving Therapy vs. Mastectomy Alone. Cancers, 2021, 13, 2150.	1.7	5
7	Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 608207.	1.3	1
8	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 741120.	1.3	2
9	Survival Outcomes of Patients With Breast Cancer Diagnosed Using Vacuum-Assisted Biopsy: A Nationwide Study From the Korean Breast Cancer Society. Journal of Breast Cancer, 2021, 25, .	0.8	2
10	Prognostic Value of Skeletal Muscle Depletion Measured on Computed Tomography for Overall Survival in Patients with Non-Metastatic Breast Cancer. Journal of Breast Cancer, 2020, 23, 80.	0.8	12
11	Correlations of female hormone levels with background parenchymal enhancement and apparent diffusion coefficient values in premenopausal breast cancer patients: Effects on cancer visibility. European Journal of Radiology, 2020, 124, 108818.	1.2	4
12	Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer. Frontiers in Oncology, 2020, 10, 558760.	1.3	9
13	Similar negative emotional impact on hair loss in neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy in young women with breast cancer from patient reported outcomes.. Journal of Clinical Oncology, 2020, 38, e19242-e19242.	0.8	0
14	Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice. Asian Journal of Surgery, 2019, 42, 314-319.	0.2	3
15	Change in microcalcifications on mammography after neoadjuvant chemotherapy in breast cancer patients: correlation with tumor response grade and comparison with lesion extent. Acta Radiologica, 2019, 60, 131-139.	0.5	10
16	Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea. Breast Cancer: Basic and Clinical Research, 2019, 13, 117822341882513.	0.6	0
17	The effect of sex hormones on normal breast tissue metabolism. Medicine (United States), 2019, 98, e16306.	0.4	5
18	Relationship between sex hormones levels and ¹⁸ F-FDG uptake by the ovaries in premenopausal woman. Radiology and Oncology, 2019, 53, 293-299.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Intraoperative Specimen Mammography for Margin Assessment in Breast-Conserving Surgery. <i>Journal of Breast Cancer</i> , 2019, 22, 635.	0.8	12
20	Menopausal Symptoms and Quality of Life Among Breast Cancer Patients with Chemotherapy-induced Amenorrhea. <i>Asian Oncology Nursing</i> , 2019, 19, 90.	0.2	3
21	Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].. <i>Journal of Clinical Oncology</i> , 2019, 37, 576-576.	0.8	6
22	Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis. <i>European Journal of Radiology</i> , 2018, 103, 84-89.	1.2	11
23	The feasibility of synthetic MRI in breast cancer patients: comparison of T_2 relaxation time with multiecho spin echo T_2 mapping method. <i>British Journal of Radiology</i> , 2018, , 20180479.	1.0	37
24	Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 87.	0.8	8
25	Small bowel obstruction from distant metastasis of primary breast cancer: a case report. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 102.	0.4	7
26	Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 182.	0.8	2
27	Clinical Characteristics and Prognosis Associated with Multiple Primary Cancers in Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2018, 21, 62.	0.8	16
28	Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 437-444.	1.1	22
29	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRRA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 502-502.	0.8	14
30	Clinical Utility of Real-Time MR-Navigated Ultrasound with Supine Breast MRI for Suspicious Enhancing Lesions Not Identified on Second-Look Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 412-420.	0.7	12
31	Radiation-related heart disease after breast cancer radiation therapy in Korean women. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 249-257.	1.1	22
32	Volume-based metabolic parameter of breast cancer on preoperative ^{18}F -FDG PET/CT could predict axillary lymph node metastasis. <i>Medicine (United States)</i> , 2017, 96, e8557.	0.4	15
33	The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are $BRCA$ Mutation Carrier. <i>Journal of Breast Cancer</i> , 2017, 20, 279.	0.8	2
34	Metabolic Activity of Normal Glandular Tissue on ^{18}F -Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Menstrual Cycles and Parenchymal Enhancements. <i>Journal of Breast Cancer</i> , 2017, 20, 386.	0.8	12
35	A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer. <i>Journal of Breast Cancer</i> , 2017, 20, 340.	0.8	4
36	A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012).. <i>Journal of Clinical Oncology</i> , 2017, 35, 517-517.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database. <i>Medicine (United States)</i> , 2016, 95, e3299.	0.4	17
38	KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients. <i>Journal of Human Genetics</i> , 2016, 61, 365-371.	1.1	17
39	Multi-center, phase II trial to evaluate the efficacy and safety of combination chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer (STORM): KBCSG-008.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12516-e12516.	0.8	0
40	Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis. <i>Journal of Breast Cancer</i> , 2015, 18, 22.	0.8	23
41	Histologic Grade and Decrease in Tumor Dimensions Affect Axillary Lymph Node Status after Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2015, 18, 394.	0.8	11
42	Validation of Risk Assessment Models for Predicting the Incidence of Breast Cancer in Korean Women. <i>Journal of Breast Cancer</i> , 2014, 17, 226.	0.8	18
43	Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). <i>BMC Cancer</i> , 2014, 14, 170.	1.1	54
44	The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study. <i>Familial Cancer</i> , 2013, 12, 75-81.	0.9	43
45	Dietary intake and breast cancer among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 1493-1501.	2.2	36
46	Usefulness of Fine-Needle Aspiration Biopsy before Performing Ultrasound-Guided Vacuum-Assisted Excision. <i>Journal of Breast Disease</i> , 2013, 1, 28-34.	0.2	2
47	æ³•ãã%µæ-°. <i>Journal of Breast Disease</i> , 2013, 1, 1-1.	0.2	0
48	Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1143-1152.	1.1	38
49	The Korean Hereditary Breast Cancer (KOHBRA) Study: Protocols and Interim Report. <i>Clinical Oncology</i> , 2011, 23, 434-441.	0.6	63
50	The Change of Practice Patterns of the Hereditary Breast Cancer Management in Korea after the Korean Hereditary Breast Cancer Study. <i>Journal of Breast Cancer</i> , 2010, 13, 418.	0.8	8
51	The Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Report. <i>Journal of Breast Cancer</i> , 2009, 12, 92.	0.8	17